Keytruda, used to treat a number of cancers, including breast cancer and skin cancer, generated more revenue than any other oncology drug last year — $14.38 billion — a 29.7 percent increase over 2019.
The next best-selling oncology drug in 2020 was Bristol Myers Squibb’s Revlimid, at $12.11 billion. Bristol Myers Squibb’s Opdivo was one of the few oncology drugs that saw revenue fall last year, down 2.9 percent to $6.99 billion, according to S&P Global.
Find the full report here.
More articles on pharmacy:
240 million Americans could get fully vaccinated against COVID-19 in 3 months
Rising costs force 39% of Americans to skip, ration meds, survey says
Millions of J&J vaccines going unused
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
